← Who reports today · Health Care
Stryker Corporation (SYK) earnings date & Q3 2026 results
Net earnings
$753M
down 12.3% y/y
Net sales
$6,520M
up 7.6% y/y
Operating income
$1,034M
down 8.9% y/y
Next report
~ Jan 28
not announced yet
The quarter in brief
Net sales rose 7.7% to $6,520 million, but net earnings fell 12.3% to $753 million and diluted EPS dropped 11.7% to $1.96. Operating income declined 8.9% to $1,034 million.
Key growth driver: SG&A grew 13.1% to $2,313 million, including $137 million of structural optimization and other special charges, of which $77 million related to the Spinal Implants sale. · by the Q3 2026 report
All figures in $M.
| Line item | Amount and change |
|---|---|
| Net sales | $6,520 · +7.6% |
| Cost of sales | $2,272 · +3.0% |
| Gross profit | $4,248 · +10.3% · 65.2% margin |
| Research, development and engineering expenses | $433 · +5.6% |
| Selling, general and administrative expenses | $2,313 · +13.1% |
| Amortization of intangible assets | $175 · −7.4% |
| Goodwill and other impairments | $293 · +301% |
| Operating income | $1,034 · −8.9% · 15.9% margin |
| Other income (expense), net | $37 · −65.1% |
| Earnings before income taxes | $997 · −3.1% |
| Income taxes | $244 · +43.5% · 24.5% effective rate |
| Net earnings | $753 · −12.3% · $1.96/sh · 11.5% margin |
Verdict: Net sales rose 7.7% to $6,520 million, but net earnings fell 12.3% to $753 million and diluted EPS dropped 11.7% to $1.96. Operating income declined 8.9% to $1,034 million.
Stryker updated full-year 2026 guidance to organic net sales growth of 6.5% to 7.0% and adjusted EPS of $14.80 to $14.90. The company repurchased $1.0 billion of stock in the quarter, and in October 2026 the Board added $3.0 billion to the repurchase program. Dividends paid in the first nine months totaled $1,012 million versus $963 million a year earlier.
Source and notation
Source: Stryker press release, 8-K EX-99.1 of 10/29/2026 (SEC EDGAR).
Open as an image: Stryker Corporation (SYK), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “Stryker Corporation (SYK) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/syk. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/syk"><img src="https://whoreportstoday.com/t/syk/img/stryker-syk-earnings-sankey.png" alt="Stryker Corporation (SYK) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/syk">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/syk/img/stryker-syk-earnings-sankey.png
<a href="https://whoreportstoday.com/t/syk">Stryker Corporation (SYK) Q3 2026 earnings chart (Who Reports Today)</a>
The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Goodwill and other impairments jumped to $293 million from $73 million; the operating margin was 15.9% versus 18.7%.
- Gross margin improved to 65.2% from 63.6%, with gross profit up 10.3% to $4,248 million.
- SG&A grew 13.1% to $2,313 million, including $137 million of structural optimization and other special charges, of which $77 million related to the Spinal Implants sale.
- The effective tax rate rose to 24.5% from 16.5%, with income taxes up 43.5% to $244 million.
- Other expense, net narrowed to $37 million from $106 million.
- MedSurg and Neurotechnology sales grew 9.2% to $3,664 million, while Orthopaedics grew 5.7% to $2,856 million; Ortho Tech grew 15.8%.
- Diluted shares declined to 384.7 million from 386.7 million; adjusted EPS rose 10.3% to $3.52.
What distorts the picture in this report and what to watch beyond the headlines.
Who runs the company now
- Kevin A. LoboChair and Chief Executive Officer [1]
- Preston W. WellsVice President, Chief Financial Officer [2]
As of 11/18/2026, per the company’s SEC filings: signatures on the latest report and leadership-change filings.
Positions and previous jobs: the company’s SEC filings. Spotted an error, or is this you and you’d like it corrected or removed? Contact us
How this is compiled
Who runs the company now comes from primary sources only: for US and Canadian companies, the CEO and CFO signatures on the latest SEC report, and a separate board chair from the proxy materials; for Russian and Kazakh issuers, the company website and its disclosures. We recheck weekly; if a name can’t be confirmed, or a leadership-change filing came out after the report, we don’t show it until it’s reviewed. Previous jobs are only what the company itself disclosed about its current leaders (the past five years of business experience in the annual report and proxy materials): employer, position and years, restated as facts, with no age, education or other personal details. If the company doesn’t disclose it, we don’t look elsewhere. Anything more than 400 days past its last check is hidden. These are public business facts from disclosures, shown to tell investors who runs the company (our legitimate interest); if this is you and you object, contact us via the link above and we’ll remove it.
Sources · 2
- SEC EDGAR: 10-Q 2026-10-30 · SEC EDGAR · 11/18/2026
- SEC EDGAR: 10-Q 2026-10-30 · SEC EDGAR · 11/18/2026
Stryker Corporation is an American multinational medical technologies corporation based in Portage, Michigan, United States. · Text: Wikipedia, CC BY-SA 4.0, abridged
The company's products are used for medical surgery and neurotechnology, which include surgical equipment, patient and caregiver safety technologies, endoscopy systems, and patient handling, emergency medical equipment, and intensive care disposable products, as well as neurosurgical, neurovascular and oral and maxillofacial surgery implant products; and orthopedic surgery, which includes implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Heads-up
- net income fell 12% y/y in Q3 2026
Net income for Q3 2026: $753M, −12% y/y. In the report's figures: costs grew faster than revenue: goodwill and other impairments +301% y/y, selling, general and administrative expenses +13% y/y, income taxes +44% y/y. Based on the Q3 2026 report.
The company's report ↗Company reports
Company guidance
| Period | Company guidance | A year ago | Implied growth |
|---|---|---|---|
| FY2026 | revenue growth +7%EPS (non-GAAP) $14.80–14.90 | revenue $25.1BEPS (GAAP) $8.40 | — |
Same quarter a year ago (ended December 31, 2025): revenue $7.17B, EPS (GAAP) $2.20
How we calculate
EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
Guidance comes from the company's earnings release (Form 8-K filed Oct 29, 2026); every figure is checked against the release text.
SYK earnings history: past report dates
| Oct 29, 2026 Thu | 4:11 pmafter market close | Sep 30, 2026 | $6.5B+8% y/y | $1.96−12% y/y |
| Jul 30, 2026 Thu | 4:09 pmafter market close | Jun 30, 2026 | $6.6B+9% y/y | $3.30+44% y/y |
| Apr 30, 2026 Thu | 4:07 pmafter market close | Mar 31, 2026 | $6.0B+3% y/y | $1.93+14% y/y |
| Jan 29, 2026 Thu | 4:11 pmafter market close | Dec 31, 2025 | $7.2B+11% y/y | $2.20+56% y/y |
| Oct 30, 2025 Thu | 4:15 pmafter market close | Sep 30, 2025 | $6.1B+10% y/y | $2.22+3% y/y |
| Jul 31, 2025 Thu | 4:12 pmafter market close | Jun 30, 2025 | $6.0B+11% y/y | $2.29+7% y/y |
| May 1, 2025 Thu | 4:10 pmafter market close | Mar 31, 2025 | $5.9B+12% y/y | $1.69−18% y/y |
| Jan 28, 2025 Tue | 4:07 pmafter market close | Dec 31, 2024 | $6.4B+11% y/y | $1.41−53% y/y |
| Oct 29, 2024 Tue | 4:09 pmafter market close | Sep 30, 2024 | $5.5B+12% y/y | $2.16+20% y/y |
| Jul 30, 2024 Tue | 4:09 pmafter market close | Jun 30, 2024 | $5.4B+9% y/y | $2.14+11% y/y |
| Apr 30, 2024 Tue | 4:11 pmafter market close | Mar 31, 2024 | $5.2B+10% y/y | $2.05+33% y/y |
| Jan 30, 2024 Tue | 4:07 pmafter market close | Dec 31, 2023 | $5.8B+12% y/y | $2.98+103% y/y |
| Nov 2, 2023 Thu | 4:20 pmafter market close | Sep 30, 2023 | $4.9B+10% y/y | $1.80−16% y/y |
| Aug 3, 2023 Thu | 4:12 pmafter market close | Jun 30, 2023 | $5.0B+11% y/y | $1.93+12% y/y |
| May 1, 2023 Mon | 4:10 pmafter market close | Mar 31, 2023 | $4.8B+12% y/y | $1.54+83% y/y |
| Jan 31, 2023 Tue | 4:07 pmafter market close | Dec 31, 2022 | $5.2B+11% y/y | $1.47−15% y/y |
Show all 16 reports since 2023Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Stryker Corporation: 15-year financials
| 2025 | 25,116 | 4,889 | 3,246 | 4,283 | 1,284 |
| 2024 | 22,595 | 3,689 | 2,993 | 3,487 | 1,219 |
| 2023 | 20,498 | 3,888 | 3,165 | 3,136 | 1,139 |
| 2022 | 18,449 | 2,841 | 2,358 | 2,036 | 1,051 |
| 2021 | 17,108 | 2,584 | 1,994 | 2,738 | 950 |
| 2020 | 14,351 | 2,223 | 1,599 | 2,790 | 863 |
| 2019 | 14,884 | 2,713 | 2,083 | 1,542 | 778 |
| 2018 | 13,601 | 2,537 | 3,553 | 2,038 | 703 |
| 2017 | 12,444 | 2,297 | 1,020 | 961 | 636 |
| 2016 | 11,325 | 2,175 | 1,647 | 1,425 | 568 |
| 2015 | 9,946 | 1,861 | 1,439 | 711 | 521 |
| 2014 | 9,675 | 1,246 | 515 | 1,549 | 462 |
| 2013 | 9,021 | 1,256 | 1,006 | 1,691 | 401 |
| 2012 | 8,657 | 1,741 | 1,298 | 1,447 | 324 |
| 2011 | 8,307 | 1,686 | 1,345 | 1,208 | 279 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
Stryker Corporation: 15-year balance sheet
| Year | Assets | Equity | Debt | Cash | Current assets | Current liabilities |
|---|---|---|---|---|---|---|
| 2025 | 47,844 | 22,420 | 15,859 | 4,011 | 14,755 | 7,794 |
| 2024 | 42,971 | 20,634 | 13,597 | 3,652 | 14,847 | 7,616 |
| 2023 | 39,912 | 18,593 | 12,995 | 2,971 | 12,518 | 7,921 |
| 2022 | 36,884 | 16,616 | 13,048 | 1,844 | 10,275 | 6,303 |
| 2021 | 34,631 | 14,877 | 12,479 | 2,944 | 10,017 | 4,549 |
| 2020 | 34,330 | 13,084 | 13,991 | 2,943 | 9,707 | 5,041 |
| 2019 | 30,167 | 12,807 | 11,090 | 4,337 | 11,058 | 4,400 |
| 2018 | 27,229 | 11,730 | 9,859 | 3,616 | 9,733 | 4,807 |
| 2017 | 22,197 | 9,966 | 7,222 | 2,542 | 7,993 | 3,485 |
| 2016 | 20,435 | 9,550 | 7,114 | 3,316 | 7,861 | 3,148 |
| 2015 | 16,223 | 8,511 | 3,998 | 3,379 | 7,943 | 3,502 |
| 2014 | 17,258 | 8,595 | 3,973 | 1,795 | 8,684 | 4,461 |
| 2013 | 15,399 | 9,047 | 2,764 | 1,339 | 8,335 | 2,657 |
| 2012 | 13,206 | 8,597 | 1,762 | 1,395 | 8,148 | 1,876 |
| 2011 | 12,146 | 7,683 | 2,268 | 905 | 7,207 | 1,840 |
$ millions, at fiscal year-end*.
* Sources
How we calculate
Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .
Cash flow
9 months ended 2026-09-30 · $M
| Line | This period | Year ago | Δ |
|---|---|---|---|
| Operating cash flowcash the business generated | 3,303 | 2,901 | +402 |
| · incl. D&A (non-cash add-back)depreciation & amortization | 1,196 | 1,153 | |
| · incl. stock-based comp (non-cash)share-based compensation | 208 | 195 | |
| Capexpurchases of property & equipment | −605 | −493 | −112 |
| Free cash flow ≈operating cash flow − capex | 2,698 | 2,408 | +290 |
| Investing activities, netcapex, acquisitions, securities | −1,011 | −4,561 | +3,550 |
| · incl. acquisitionsbusinesses net of cash acquired | −481 | −4,950 | +4,469 |
| Financing activities, netdebt, buybacks, dividends | −2,998 | 1,206 | −4,204 |
| · incl. buybacksrepurchases of common stock | −1,000 | 0 | −1,000 |
| · incl. dividends paid | −1,012 | −963 | −49 |
| FX effect on cash | −34 | 58 | −92 |
| Net change in cash | −740 | −396 | −344 |
How to read the table
Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.
Shareholders’ equity at Sep 30, 2026: $23.5B (50% of total assets). Compare with other S&P 500 companies →
Corporate governance
2/2good
- Feb 2026Cover of the 2025 10-K: one registered class of common stock — Common Stock, $.10 par value (NYSE: SYK). sec.gov ↗
- Feb 2026Diluted weighted average shares +1.6% over 2020–2025; SBC $243M — 1.0% of $25.1B revenue. data.sec.gov ↗
2 more facts and scoring
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
- Feb 2026Declared dividend: $2.585 (2021) → $2.835 → $3.05 → $3.24 → $3.40 per share (2025). sec.gov ↗
- Feb 202610-K: in 2025 the SEC and DOJ notified the company they had closed their FCPA inquiries; no shareholder disclosure suits. sec.gov ↗
Scoring: 2.0 with no deductions = 2.0 (single share class, diluted shares +1.6% over 5 years, dividend raised every year, no shareholder lawsuits; SEC/DOJ FCPA inquiries closed in 2025)
- Share classes
- 10-K cover: one class — Common Stock $.10 (NYSE: SYK) plus euro-denominated notes.
- Dilution
- Diluted shares +1.6% over 2020–2025; deals (Wright Medical, Inari and others) paid in cash; SBC 1% of revenue.
- Disclosure
- Full reporting, no violations.
- Dividends
- Declared dividend rising: $2.585 (2021) → $3.40 (2025).
- Lawsuits & regulators
- 10-K: product liability (implants) and patent suits; the SEC and DOJ closed their FCPA inquiries in 2025 with no action; the 2013/2018 SEC FCPA cases are not deducted under the methodology; no shareholder lawsuits.
- Related parties
- No material related-party transactions.
How the score works · checked as of Oct 2026
Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap
Stryker Corporation (SYK) earnings: FAQ
When is SYK's next earnings date?
We have not yet seen an announcement of the date from Stryker Corporation (SYK). Based on last year's report on Jan 29, 2026, the next report is expected around Jan 28, 2027.
What time does SYK report earnings?
Stryker Corporation usually reports after market close: its latest results release was filed with the SEC at 4:11 pm ET on Oct 29, 2026.
When did SYK last report earnings?
Stryker Corporation reported Q3 2026 results on Oct 29, 2026.
What has Stryker Corporation guided for FY2026?
Company guidance for FY2026: revenue growth +7%; EPS (non-GAAP) $14.80–14.90. A year ago (FY2025): revenue $25.1B, EPS (GAAP) $8.40. Source: the company's earnings release (Form 8-K filed Oct 29, 2026).
Where can I find Stryker Corporation's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to SYK's filings; this page breaks the latest report down in a Sankey chart.
What was SYK's net income in Q3 2026?
Stryker Corporation reported net income of $753M for Q3 2026 (−12.3% year over year), under US GAAP.
Does Stryker Corporation pay dividends?
Yes. In 2025, Stryker Corporation paid $1,284M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.
How has Stryker Corporation's revenue changed since 2011?
Per its 10-K filings, revenue grew 3x: $8,307M in 2011 and $25,116M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
Get it every Monday: who reports this week
Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.
More reports: TECH · Q4 FY2026 · TMO · Q3 2026 · UHS · Q3 2026 · UNH · Q3 2026 · VEEV · Q2 FY2027 · VRTX · Q3 2026 · VTRS · Q2 2026 · WAT · Q3 2026 · WST · Q3 2026 · ZBH · Q3 2026 · all reports